Paper Details

  1. Home
  2. Paper Details

Recent developments in iron chelation therapy.

Author: CarioH, Janka-SchaubG, JanssenG, JarischA, KohneE, StraussG

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Iron chelation therapy options have expanded with the development of oral chelators like deferiprone and deferasirox, offering more tailored treatment for transfusional hemosiderosis.
Paper Details　
Original Abstract of the Article :
Since 1962, desferrioxamine (deferoxamine, DFO) has been utilized for the treatment of secondary hemosiderosis. For about 30 years, DFO therapy has been performed as nightly continuous subcutaneous infusion. About 20 years ago, the first oral iron chelator (deferiprone, DFP) was presented. Concerns ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-2007-973845

データ提供：米国国立医学図書館（NLM）

Iron Chelation Therapy: A Journey to Improved Health

The field of iron chelation therapy, like a caravan navigating a treacherous desert landscape, has undergone a remarkable transformation. This study charts the advancements in this critical area, examining the evolution of treatment options for secondary hemosiderosis. The researchers highlight the development of new chelating agents, such as deferiprone (DFP) and deferasirox (DSX), providing a broader range of treatment possibilities and enhancing the quality of life for patients.

Advancements in Iron Chelation Therapy

The study reveals significant progress in iron chelation therapy. The introduction of new chelating agents, such as deferiprone (DFP) and deferasirox (DSX), offers patients with transfusional hemosiderosis a wider array of treatment options. These advancements, like the discovery of a hidden oasis, provide hope for improved health and well-being for those affected by iron overload.

A New Era in Iron Chelation Treatment

This study marks a new era in iron chelation treatment. The availability of three commercially available chelating agents empowers healthcare professionals to tailor treatment plans to individual patients' needs. This personalized approach, like a skilled navigator guiding a caravan, can lead to more effective treatment and ultimately, a better quality of life for patients.

Dr.Camel's Conclusion

The advancements in iron chelation therapy, like the emergence of a new oasis in the desert, offer hope for a brighter future for those battling iron overload. These groundbreaking discoveries have the potential to transform the lives of countless patients, providing them with the tools they need to combat this debilitating condition.

Date :
  1. Date Completed 2007-09-12
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

17525910

DOI: Digital Object Identifier

10.1055/s-2007-973845

Related Literature

Article Analysis
・Side Effects of deferasirox
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.